



Contacts: Meg McGilley
Chief Financial Officer
(858) 509-3670

Rob Whetstone
PondelWilkinson Inc.
(310) 279-5963

Somaxon Pharmaceuticals to Announce Results of Initial Phase 3 Clinical Trial of SILENOR™ for the Treatment of Adults with Chronic Insomnia and Host Conference Call on Monday, April 10

SAN DIEGO, CA – April 9, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today said that, tomorrow morning, Monday, April 10, the company plans to issue results from its initial Phase 3 clinical trial of SILENOR™ (doxepin HCl) for the treatment of adults with chronic insomnia. Additionally, Somaxon management will host a conference call Monday morning at 8:30 a.m. Eastern Time to review the results of this Phase 3 trial.

Callers may participate in the conference call by dialing (800) 776-0816 (domestic) or (913) 981-5556 (international), and entering passcode 9654807. A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (888) 203-1112 (domestic) or (719) 457-0820 (international), and entering passcode 9654807. The conference call also will be available to interested parties through a live audio Internet broadcast at www.somaxon.com and www.opencompany.info. The call will be archived and accessible at both sites for approximately one year.

The company also said that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the BIO 2006 Business Forum in Chicago, IL on Tuesday, April 11, 2006 at 3:30 p.m. Central Time. The presentation will take place at the McCormick Convention Center, Level 3, Exhibit Hall A, Room B.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin hydrochloride), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and in a pilot Phase 2 clinical trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development. For more information, please visit the company's Web site at www.somaxon.com.

###